Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 19Terminated 9Unknown 2Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Thromboembolism 1Stomach Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Duodenal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Dalteparin × Clear all
NCT03139487 2020-01-06

PRIORITY

Asan Medical Center

Phase 2 Unknown
176 enrolled
GastrointestinalSarcoma

Biliary Tract Neoplasms, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

NCT00519805 2011-08-08

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
2,200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡